Investors are placing a significant bet on the iShares MSCI World ETF (URTH) even as it navigates a complex web of challenges. The fund attracted nearly half a billion dollars in just five trading days, pushing its assets under management to approximately $7.5 billion. This robust inflow persists despite a brewing fee war, new trade tariffs, and the imminent arrival of the most significant index methodology change in years.
The competitive landscape for global equity ETFs intensified in April 2026 when Invesco slashed the management fee on its MSCI World UCITS ETF to 0.05%. This move highlights a substantial 19-basis-point gap compared to URTH’s total expense ratio of 0.24%. Rivals UBS and BNP Paribas had previously lowered fees on their competing products to 0.06% in May and September 2025, respectively. Morningstar’s latest Bronze rating for the iShares fund noted it could be more competitively priced, yet major institutions are not retreating. The Royal Bank of Canada, for instance, increased its stake by 17.5% in Q4 2025 to about two million shares, suggesting liquidity and track record currently outweigh pure cost considerations for large allocators.
Political headwinds are adding another layer of complexity. On April 2, 2026, President Trump signed an order imposing a 100% tariff on patented pharmaceuticals under Section 232 of the Trade Expansion Act, set to take effect in late July. The policy aims to relocate drug manufacturing to the US, with reduced rates of 15% for imports from the EU, Japan, South Korea, and Switzerland, and 10% for UK imports. This directly impacts URTH’s substantial healthcare sector holdings. Analysts further estimate the broader trade measures could dampen global growth and add roughly 0.5 percentage points to inflation, pressuring profit margins for the index’s largest constituents.
Technology giants, which comprise over 26% of the portfolio, face parallel pressures. Heavyweights Nvidia, Apple, and Microsoft—collectively 13.6% of the fund—remain highly dependent on Asian supply chains strained by ongoing trade tensions.
Should investors sell immediately? Or is it worth buying MSCI World ETF?
The most transformative event on the horizon, however, is structural. In May 2026, MSCI will fundamentally overhaul its free-float calculation framework, introducing a new system with three categories and distinct rounding rules. Because the March rebalancing was intentionally minimized, market observers anticipate a significantly higher portfolio turnover in May. Early signs of realignment emerged in Q1 2026, with US equities being net reduced for the first time in years and new positions like AST SpaceMobile and FTAI Aviation being added.
This new methodology will also set the stage for a potential seismic shift: the integration of SpaceX. The space exploration company confidentially filed for an IPO with the SEC in early April 2026, targeting a valuation of $1.75 trillion. Its inclusion would trigger billions in passive fund flows and markedly increase the US equity and aerospace weight within the ETF. In a separate but relevant move, MSCI has withdrawn a proposal to exclude companies with high crypto exposure from its core indices, removing potential selling pressure on URTH from a reweighting of stocks like Strategy Inc.
For income-focused shareholders, the next key date is June 15, 2026, when the ETF trades ex-dividend. The fund’s dividend growth recently exceeded 20% year-over-year, offering a silver lining amidst the quarter’s turbulence. The coming months will test whether the ETF’s scale and reputation can continue to attract capital while its underlying composition is reshaped by both policy and methodology.
Ad
MSCI World ETF Stock: Buy or Sell?! New MSCI World ETF Analysis from April 10 delivers the answer:
The latest MSCI World ETF figures speak for themselves: Urgent action needed for MSCI World ETF investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 10.
MSCI World ETF: Buy or sell? Read more here...










